trending Market Intelligence /marketintelligence/en/news-insights/trending/lqjvV-ZWcpmCmgJ22StiqQ2 content esgSubNav
In This List

VistaGen, BlueRock sign sublicense agreement for stem cells technologies

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


VistaGen, BlueRock sign sublicense agreement for stem cells technologies

VistaGen Therapeutics Inc. entered into exclusive sublicense agreement with BlueRock Therapeutics for rights to certain proprietary technologies relating to the production of cardiac stem cells for the treatment of heart disease.

The company licensed exclusive rights of the cardiac stem cell technologies from University Health Network, a Canadian research hospital, under a strategic research agreement.

Under the sublicense agreement, VistaGen will receive an up-front cash payment of $1.25 million and potential future milestone payments and royalties from BlueRock.

BlueRock is a stem cell research company established by Bayer AG and Versant Ventures.